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Abstract: Chronic obstructive pulmonary disease (COPD) represents a major global cause 
of disability and death. COPD is currently the fourth most common global cause of death and 
also exerts an enormous toll on patients quality of life. The present database analysis aimed 
to identify clinical trials using ﬁ  xed combination therapies that have assessed the impact on 
the patients quality of life. Within the different studies, questionnaires including the George’s 
Respiratory Questionnaire (SGRQ) the Chronic Respiratory Disease Questionnaire (CRDQ) 
and the Clinical COPD Questionnaire (CCQ) were used and differing results in quality of life 
were obtained when combination therapies such as ﬂ  uticasone/salmeterol or ﬂ  uticasone/sal-
meterol were compared with monotherapies. While there were some differences in favor of 
combination therapies reported when the combination therapy was compared to inhaled steroid 
monotherapy there were no consistent differences when combination therapies were compared 
to bronchodilator monotherapies. Future trials will lead to a proof-of-principle stage concerning 
the use of combination therapies.
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Introduction
Chronic obstructive pulmonary disease (COPD) has evolved as one of the major 
global causes of death and disability over the past decades (Hansen-Flaschen 2003). 
The global burden of disease studies reported in alarming increase in COPD preva-
lence (Murray and Lopez 1997a, b, c). As with other respiratory diseases, COPD 
is related to exposure against air pollutants (Boschetto et al 2006; Groneberg-Kloft 
et al 2006). In 1990, the disease was classiﬁ  ed as the sixth most common global 
cause of death. For the year 2020, it was predicted that COPD would become the 
third commonest cause of death irrespective of public-health intervention. Also, 
COPD was reported to become the fourth most important disease leading to dis-
ability by the year 2020 (Murray and Lopez 1997a, b, c). WHO studies lead to the 
assumption that these predictions are likely to be correct since COPD had become 
the fourth commonest global cause of mortality (Murray et al 2001). The National 
Heart, Lung, and Blood Institute reported for the US that COPD has increased in 
importance during the past two decades in contrast to all other causes of chronic 
disability (National Heart 2002). Concomitant with these increases, COPD is more 
often diagnosed by general practitioners as reported for the UK: Here, an increase in 
COPD diagnosis was reported for the period 1990–1997 (Soriano et al 2000) which 
was paralleled by an increase in COPD-related hospital admissions (Calverley and 
Walker 2003). In the context of disease management, acute exacerbations are impor-
tant clinical events in COPD and largely contribute to a decline of quality of life. 
The life quality in patients with COPD as assessed, ie, by activities of daily living, 
emotional functioning, social-role functioning, and recreational pastimes was found 
to be impaired relative to healthy subjects on all dimensions (McSweeny et al 1982; International Journal of COPD 2007:2(4) 552
Groneberg-Kloft et al
Jones et al 1992; Ketelaars et al 1996; Hajiro et al 1998). 
Depression was the preponderant emotional disturbance 
reported, difﬁ  culties with home management and reduction 
in social interaction were the primary social-role deﬁ  cits 
while sleep and rest, mobility, and a variety of recreational 
pastimes were also severely affected (McSweeny et al 
1982). Patients with COPD also only have low expecta-
tions of medical care, and many of them do not complain 
despite substantial disease-associated disabilities (Rennard 
et al 2002). This reluctance to ask for an increased attention 
may be related to increased emotional disturbances such as 
depression (McSweeny et al 1982).
As COPD is characterized by a variable pathology among 
patients (Welte and Groneberg 2006) and there are no speciﬁ  c 
“COPD-drugs” available, an international standardization 
of disease management has been difﬁ  cult to establish over 
the past years. However, with an increasing signiﬁ  cance of 
COPD concerning the global burden of disease, important 
guidelines to optimize disease management were proposed 
by several thoracic societies and international organizations 
in the past years (Society 1987; Siafakas et al 1995; Fabbri 
et al 1998; Balter et al 2003). The most prominent guide-
lines are the Global initiative for chronic Obstructive Lung 
Disease (GOLD) which was initiated by the WHO and the 
US National Heart, Lung, and Blood Institute (Pauwels et al 
2001) and the international guidelines of the American Tho-
racic Society (ATS) and the European Respiratory Society 
(ERS) (Celli and MacNee 2004).
Prior to assessing the impact of drug therapies it is crucial 
to deﬁ  ne the disease entity since there have been various 
approaches towards the deﬁ  nition in the past decades. The 
clinical diagnosis of COPD largely relies on the patient’s 
history and abnormal lung function tests. As COPD is char-
acterized by a variable pathology and the molecular mecha-
nisms are not completely understood, it has been difﬁ  cult 
to agree on a simply disease deﬁ  nition. First approaches 
based on epidemiological features of chronic cough and 
sputum production such as lasting of symptoms for 3 months 
over a period of at least 2 years (chronic bronchitis) or on 
pathological features such as the identiﬁ  cation of emphy-
sema in COPD airway tissues. However, these approaches 
did not prove to be efﬁ  cient in the clinical management of 
the disease.
A keystone in the approach towards a rational disease 
deﬁ  nition is represented by the ﬁ  rst reports that related dis-
ability and death in COPD to a progressive decrease in the 
forced expiratory volume in 1 second (FEV1) (Fletcher and 
Peto 1977; Peto et al 1983).
It is now generally accepted that COPD diagnosis cru-
cially relies on the presence of airﬂ  ow obstruction deﬁ  ned 
as decreased FEV1 to FVC (forced vital capacity) or vital 
capacity ratio. However, it should also be critically remarked 
that lung function only partly correlates to other prognosis 
parameters. Therefore, the BODE (body-mass index, airﬂ  ow 
obstruction, dyspnea, and exercise capacity index) score was 
developed (Celli et al 2004).
Extending the basic functional features, the GOLD 
guidelines introduced persistent inﬂ  ammation and the 
potential presence of noxious stimuli to the disease 
deﬁ  nition. With the persistent inﬂ  ammation being an 
accepted feature of the disease, the question arises whether 
combination therapies with inhaled bronchodilators and 
steroids are superior to monotherapies with inhaled bron-
chodilators (Table1). Therefore the present analysis aims 
to assess the effects of the ﬁ  xed combination therapies 
budesonide/formoterol and ﬂ  uticasone/salmeterol on the 
quality of life.
Methods
Sources
Clinical trials were identiﬁ  ed by the use of the PubMed, 
the Cochrane Central Register of Controlled Trials (CEN-
TRAL), EMBASE and CINAHL. Also, hand-searching 
of pulmonary journals and meeting abstract booklets was 
performed. The terms “COPD” and “chronic obstruc-
tive pulmonary disease” were searched in combination 
with the terms (quality of life), (*steroid or steroid* OR 
corticosteroid*) and ((beta* and agonist*) and long*) or 
((beta* and adrenergic*) and long*) and (formoterol and 
Table 1 Stage-speciﬁ  c therapy of stable COPD. Potential use of 
combination therapy with inhaled corticosteroid and bronchodi-
lator instead of bronchodilator monotherapy
Stage 0:  At Risk •    Avoidance of risk factors, inﬂ  uenza 
vaccination
Stage I: Mild •    Add: short-acting bronchodilator when 
needed
Stage II: Moderate •    Add: regular treatment with one or more 
long-acting bronchodilators
 •    Question: Is ﬁ  xed combination therapy 
superior?
 •    Add: rehabilitation
Stage III: Severe •    Add: inhaled corticosteroids if repeated 
exacerbations
Stage IV:   Very severe •    Add: long-term oxygen if chronic respira-
tory failure
 •    Consider: Surgical optionsInternational Journal of COPD 2007:2(4) 553
Fixed therapy and quality of life
budesonide) or Symbicort and (ﬂ  uticasone and salmeterol) 
or Seretide or Advair. The most recent search was run in 
July 2007.
Analysis
The analysis was performed by independently identifying 
abstracts of trials which appeared relevant. Then the full 
text of each study was used and trials were selected trials 
for inclusion in the analysis. After a preliminary assessment 
of all studies was performed to conﬁ  rm the basic require-
ments, the methodological quality of the included studies 
was assessed using accepted Cochrane criteria with grade A: 
adequate concealment, grade B: uncertain, grade C: clearly 
inadequate concealment.
Results
Data selection
Using database searches a large number of entries related to 
COPD (Figure 1) and quality of life (Figure 2) was found 
that was further classiﬁ  ed and analysed for publication dates 
(Figure 3) and the following study parameters.
Trial quality
All included trials had a randomized, double-blind, placebo 
controlled parallel group design. Methods of randomization 
were described only in one study (Mahler 2002). Method of 
blinding was not fully described in all trials. All included 
participants suffered from COPD, with variable deﬁ  nition 
of COPD and reversibility.
Health-related quality of life
Most studies assessed the quality of life either using the 
St. George’s Respiratory Questionnaire (SQRQ) or the 
Chronic Respiratory Disease Questionnaire (CRDQ), partly 
only reporting single domains. Concerning the analysis if 
the SQRQ it needs to be criticized that most of the studies 
only reported the mean values of the SQRQ scores. In this 
respect, it should have been important to know if there is a 
difference between the numbers of patients with an increase 
in the score of 4 units (cut-off point for signiﬁ  cant improve-
ment). Also, a separate analysis of single domains should 
not be performed.
Fluticasone/salmeterol
To assess the health-related quality of life the St. George’s 
Respiratory Questionnaire (SGRQ) (Calverley et al 2003a; 
Wouters et al 2005), the Chronic Respiratory Disease 
Questionnaire (CRDQ) (Mahler et al 2002; Hanania et al 
2003) and the Clinical COPD Questionnaire (CCQ) (Wouters 
et al 2005) were used. For the global SGRQ score one study 
(Calverley et al 2003a) reported a signiﬁ  cant difference favo-
rable for a combination therapy in comparison to ﬂ  uticasone 
monotherapy (score was 1.4 units lower) after 1 year of 
therapy. Also a signiﬁ  cant difference favorable for a com-
bination therapy in comparison to salmeterol monotherapy 
was found after 44 weeks in this study (score was 2.24 units 
lower) (Calverley et al 2003a).
A further study reported a signiﬁ  cant difference after 
24 weeks of combination therapy (500 μg ﬂ  uticasone) in the 
CDRQ total score and in the dyspnea score in comparison to 
ﬂ  uticasone monotherapy (the total score was 4.8 units higher  Figure 1 Database analysis for COPD. Search date: 2007-7-24.
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Figure 2 Database analysis for COPD and quality of life. Search date: 2007-7-24.
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than the monotherapy score) (Mahler et al 2002). However, 
there were no differences in comparison to salmeterol 
monotherapy (Mahler et al 2002). The study using a lower 
dosage (250 μg ﬂ  uticasone) (Hanania et al 2003) did not ﬁ  nd 
any signiﬁ  cant differences in comparison to monotherapy. 
The CRDQ total score increased after 24 weeks of therapy 
with combination therapy (250 and 500 μg ﬂ  uticasone) with 
10 units in comparison to baseline values. The dyspnea score 
increased with 3.9 (250 μg ﬂ  uticasone) and 4.2 (500 μg ﬂ  u-
ticasone) units. For the CDSQ one study found a signiﬁ  cant 
difference in favor of the combination therapy (Mahler et al 
2002) in comparison to the ﬂ  uticasone monotherapy. How-
ever, there were no differences in comparison to the salmeterol 
monotherapy. The same results were reported for the study 
with the lower dosage (Hanania et al 2003). Absolute differ-
ences in these scores in comparison to the baseline values 
were similar in both studies (Hanania et al 2003).
An important contribution towards the understanding 
of effects of combined therapies on quality of life is the 
TORCH study (Calverley et al 2007). This randomized, 
double-blind trial compared salmeterol at a dose of 
50 microg plus ﬂ  uticasone propionate at a dose of 500 
microg twice daily (combination regimen) with placebo, 
salmeterol alone, or ﬂ  uticasone propionate alone for a period 
of 3 years. The primary outcome was mortality from any 
cause for the comparison between the combination regimen 
and placebo. While the reduction in death from all causes 
among patients with COPD in the combination-therapy 
group did not reach the predetermined level of statistical 
signiﬁ  cance, signiﬁ  cant beneﬁ  ts were present in all other 
outcomes measured (Calverley et al 2007). Concerning the 
quality of life, the St. George’s Respiratory Questionnaire 
(SGRQ) was used. Total scores on the St. George’s 
Respiratory Questionnaire initially improved from baseline 
in all groups, with the greatest changes occurring in the 
combination-therapy group (mean score at baseline, 48.7, 
with a mean reduction of 3.0 units averaged over 3 years), 
as compared with the placebo group (a mean score of 48.4 at 
baseline, with an increase of 0.2 unit in the placebo group) 
(Figure 4). Averaged over 3 years, the health status in the 
combination-therapy group was signiﬁ  cantly better than in 
the groups receiving placebo, salmeterol alone, or ﬂ  uticasone 
propionate alone (Calverley et al 2007).
Budesonide/formoterol
When the combination budesonide/formoterol was assessed 
for effects on quality of life data from two studies demon-
strated a signiﬁ  cant effect in favor of budesonide/formot-
erol compared with placebo of –6.06 units on the SGRQ; 
95%CI –7.90 to –4.22 (Szafranski et al 2003; Calverley 
et al 2003b; Nannini et al 2004). However, there appeared 
to be a high level of heterogeneity when these data were 
pooled (I2 71.8%) as indicated by a Cochrane analysis. 
Random effects modelling also generated a signiﬁ  cant 
effect (weighted mean difference WMD –5.8 units; 95% 
CI –9.32 to –2.28. The improvement from baseline in the 
budesonide/formoterol group was 3.9 units (Szafranski et al 
2003). This was not dissimilar to change scores from post 
run-in treatment in the other study (Calverley et al 2003b). 
Comparisons with monotherapies were not fully reported 
in the studies but Szafranski et al reported similar effects 
observed in patients treated with formoterol monotherapy 
(3.6 units) (Szafranski et al 2003).
Discussion
COPD is characterized by slowly progressive development 
of a poorly reversible airﬂ  ow limitation and inﬂ  ammatory 
airway changes. Since it is estimated to be currently the 
fourth most common global cause of death and success of 
pharmacotherapy is still limited, new therapeutic regimen 
need to be evaluated. One of the most promising approaches 
should be the use of combined inhaled betamimetics and 
corticosteroids with the corticosteroids targeting the features 
of inﬂ  ammation and mucus secretion and thus inhibit-
ing further symptoms including airﬂ  ow limitation and 
cough (Figure 5). The present analysis assessed the 
effects of combination therapies on the quality of life. 
There were differing results concerning quality of life 
when ﬂ  uticasone/salmeterol was compared with inhaled 
steroids alone while there were no signiﬁ  cant differences 
present between ﬂ  uticasone/salmeterol and long-acting 
Figure 3 Database analysis for COPD and quality of life and publication dates. 
Search date: 2007-7-24.
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beta-agonist in quality of life scores. The combination 
budesonide/formoterol was also shown to improve symp-
toms when compared with the budesonide monotherapy 
but not with formoterol. There were differing results in 
quality of life scores when budesonide/formoterol was 
compared with monotherapies.
It can be assumed that the combination of inhaled corti-
costeroids and salmeterol led to beneﬁ  ts over monotherapies 
on certain clinical outcomes but not in others. Differences 
in the treatment protocols in the budesonide/formoterol 
combination studies may explain the differences between 
health status scores. Although differences between combina-
tion therapies and placebo were statistically signifcant, the 
difference from the study of Calverley et al suggested that 
the combination of inhaled steroids and betamimetics led 
to a clinically relevant advantage compared with placebo 
treatment (Calverley et al 2003b). This difference may be 
interpreted with caution due to a pre-treatment with high 
dose prednisolone and formoterol, leading to an increase of 
4.5 units in the SGRQ.
Future trials will lead to a proof-of-principle stage concern-
ing the use of combination therapies. In these studies, com-
binations should be compared with separate administrations 
of long acting beta-agonists and inhaled corticosteroids. 
Of course, the design should be in a double-dummy design 
fashion in large scale multi-centre studies. These studies 
should also include an assessment of the patient compliance 
and the patient preference which has not been accomplished 
in the presently available studies. Also, pharmacoeconomic 
studies could be helpful to assist health agencies.
In summary, it can be stated that while there were some 
differences in favor of combination therapies reported when 
the combination therapy was compared with inhaled steroid 
monotherapy there were no consistent differences when 
combination therapies were compared to bronchodilator 
monotherapies. Future trials are needed to lead to a proof-
of-principle stage.
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